March 17, 2010: BayBio NEST | 7th Annual Life Sciences Investor and Entrepreneur Roundtables
The Entrepreneur and Investor Roundtables event is a unique event designed to facilitate introductions, dialogs and establish connections between life science entrepreneurs and investors. This event provides early stage companies with an accessible first step into the capital markets while providing investors a first look at intriguing innovations. The Entrepreneur and Investor Roundtables event is well known for its iconic ‘speed-dating’ format. Each year, VC firms and Angel Investors listen to brief pitches from dozens of biotech entrepreneurs. In Palo Alto. Detailed Information

March 23: BioFacilities | Industry Knowledge for the Non-Scientist
Further your understanding of the unique real estate and facility requirements of the dynamic and highly regulated biotech and pharmaceutical industries. Be more strategic in the development and implementation of economic development strategies targeting this growth industry by understanding the language of the industry’s built environment needs. Advance your knowledge of key performance and specific uses driving the cost of developing and operating these technical facilities. Enhance your ability to provide consultative representation to property owners and tenants. Learn from well-regarded Biotech Primer instructors that have the skill and hands-on experience to teach individuals drawing from a wide variety of professions in an engaging environment. In Menlo Park.Detailed Information

March 25, 2010: Therapeutic Breakfast Series | Establishing and Successfully Managing Strategic Alliances
The current economic climate and market pressures are forcing a change in strategy for both established and emerging life sciences companies. The IPO market is gone. The VC funding is dry. Companies, seeking to deliver new treatments and cures, are forming alliances with larger organizations at a faster pace. Some are even saying that we are witnessing a fundamental change, where success will depend on a company's capacity to manage multiple relationships as part of a larger collaborative network. To be successful, companies will need to effectively develop and manage alliances, they must also learn how to remain relevant to their partners and be flexible enough to evolve with changes in the partner's strategy. Join us for a panel of expert Alliance executives to learn how to become "alliance capable" and thrive through collaborations in the new environment. In Redwood City. Detailed Information

April 7, 2010: BayBio2010 | Life Science Innovation: Drivers and Barriers
BayBio2010 is a one-day conference focusing on Northern California's strength in life sciences innovation. This conference will examine the fundamental questions of who pays for biotech innovation and why in this unprecedented environment. It will focus on how the current financing environment and new sources of capital affect business models, development and commercialization strategies. In doing so, BayBio2010 will consider government initiatives, such as healthcare reform, clean energy legislation and American Recovery and Reinvestment (ARRA) funding, and effects of these programs on therapeutic, diagnostic and clean tech companies. Additionally, the conference will review new trends in public markets, venture investment, M&A and partnering with larger companies and how they affect the life sciences research and development process. Finally, BayBio2010 will investigate how changing consumer behavior and resulting economic realities factor into biotech company strategies. Located at the Hyatt Regency San Francisco Airport: 1333 Bayshore Highway Burlingame, CA.Detailed Information

April 15, 2010: Venture Spotlight | A Tailor Made Approach: Personalized Medicine
The crisis of health care economics is now frighteningly familiar to us all, driven by advancing technology often coupled with increasing cost. Personalized Medicine is our greatest hope for remediation of this rising economic tsunami. Decades of advances in molecular biology are now delivering important new diagnostics for Personalized Medicine (PMDx) to determine the patient's response, resistance or toxicity risk before or during treatment, in order to optimize the selection of medical treatments from amongst the alternative options. Patients benefit enormously by not wasting valuable months of treatment time and not undergoing the side effects and physical insult of ineffective or toxic treatments like chemotherapy in cancer. In Palo Alto. Detailed Information

April 22, 2010: Therapeutic Breakfast Series | Preparing for Coverage & Reimbursement: Demonstrating Value
The U.S. payer landscape is an ever-changing, complex mix of public and private payers and plan sponsors / administrators. Payer policies are becoming increasingly focused on a product’s value proposition, its value arguments, and its comparison against products in the same or similar therapeutic categories. Payers are becoming more selective in determining preferred products and more apt to apply coverage criteria / restrictions to non-preferred products. The cost shift trend to increase patient out-of-pocket co-pay / coinsurance continues, especially with specialty products. To ensure product access at launch, it is important for companies to identify and develop the payer value proposition and supporting arguments concurrent with the clinical program development. Join our panel to learn about the critical elements and timing for development of a successful coverage & reimbursement strategy, the current and emerging payer trends that will impact products in your development portfolio, and jump start the roadmap for your commercial launch. In Redwood City. Detailed Information

April 29, 2010: BayBio NEST | Technology Showcase at SRI International
The 2010 Technology Showcase at SRI International provides a sneak peak at the science within the organization often before it is published or patented. Network with scientists and entrepreneurs behind the work. SRI's Biosciences Division provides target identification, lead discovery/optimization, vaccine development, neuropharmacology research in sleep and pain, microbiology, efficacy models, comprehensive toxicology, PK/ADME, formulation, analytical chemistry, cGMP manufacturing, QA, IND preparation and government grant teaming services. In Menlo Park. Detailed Information

May 11, 2010: Medical Device Breakfast Series | How the FDA's 510(k) Programs Are Changing
Medical device start-ups face intense competition for a finite amount of available capital funding. With fears growing among investors that 510(k) clearances are no longer as quick, easy and inexpensive as they used to be, funding for companies hoping to enter the market via 510(k) is drying up. Many of them are no longer seen as a guaranteed low-risk investment. How real are these concerns? How is the FDA's 510(k) program changing? What are the real-life experiences of companies that have recently used the process? A panel of regulatory and business experts will share their up-to-date knowledge, so you can decide for yourself whether your 510(k) strategy is still viable or in need of re-evaluation. In Palo Alto. Detailed Information

May 12: BayBio Executive Series | Managing the Board
The Board of Directors should be one of the strongest assets a company possesses. It is the one asset that can be both long term and strategic as well as short term and operational. The Board of Directors can function to provide leadership, to be an advisor, to be a sounding board and to even help with implementation in certain circumstances. Within this scope of potential involvement, the board members need to be strategically managed like any other asset. This hard task falls on the CEO, who is charged with maintaining a vibrant and productive board, strategic recruitment, resolving conflicts of interest, aligning visions of the board and executive team, executing effective communications, evaluating board member performance to ensure each director is providing necessary value to the company, and dealing with disruptive or inadequate board members. Attending life sciences CEOs and CFOs will be able to gather and share unique personal insights and recommendations of how to work most effectively with a Board of Directors in both public and private company settings. Open to C Suite Executives of Life Sciences Companies Only. This event is by invitation only and the invitation is not transferrable. Detailed Information

May 19: California Life Sciences Day
Join leaders in biotechnology, medical devices, pharmaceuticals and biomedical research in Sacramento on Wednesday, May 19, 2010 to build support for the issues that matter most to California's medical innovators. Attendees will participate in face-to-face meetings with legislators and state government officials, enjoy a networking luncheon and join legislators and their staffs at a closing reception. By joining forces and speaking with one voice, we can successfully advocate the collective economic impact and human value of our work. In Sacramento. Detailed Information